A 101-patient, multicenter study presented at the annual EuroPCR conference showed that use of Medtronic's 2-mm zotarolimus-eluting stent, Resolute Onyx, for patients with coronary artery disease in extra-small vessels met its primary endpoint at 12 months. Use of the stent demonstrated high rates of lesion, device and procedure success, as well as a 5% rate of major adverse cardiac events, zero stent thrombosis and zero cardiac deaths.
Study shows positive results for Medtronic's Resolute Onyx stent
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.